Current treatment status-Undergoing active treatment-No response Page 2 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Treatment options for patients with recurrent or non-responsive Hodgkin lymphoma

Posted by on Jul 9, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviewed current treatment options for patients with Hodgkin lymphoma (HL) that has come back (relapsed) or stopped responding to treatment (refractory). Some background Chemotherapy remains the standard first-line treatment for HL. One of the most commonly used regimens is ABVD (doxorubicin, bleomycin, vinblastine,...

Read More

Searching for patients with recurrent or non-responsive lymphoma to try this new treatment option

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1 study is evaluating the safety and effectiveness of a new T-cell therapy combined with nivolumab (Opdivo) for patients with lymphoma that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This study is recruiting in Washington, D.C. and Salt...

Read More

Searching for patients with relapsed or unresponsive non-Hodgkin lymphoma to try a new cell therapy

Posted by on Jun 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This Phase 2 study is evaluating the safety and effectiveness of a new T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The main outcomes to be measured will be the number of patients who experience side effects and overall response after treatment. This trial is recruiting...

Read More

Evaluating RBD chemotherapy for recurrent or non-responsive non-Hodgkin lymphoma

Posted by on Jun 21, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated how safe and effective RBD (rituximab, bendamustine, and dexamethasone) chemotherapy was for patients with B-cell non-Hodgkin lymphoma (NHL). This study concluded that this new regimen showed promising effectiveness for these patients. Some background Chemoimmunotherapy remains the standard first-line treatment...

Read More

Looking for older patients with acute myeloid leukemia to test a new treatment combination

Posted by on Jun 14, 2019 in Leukemia | 0 comments

In a nutshell This study is evaluating how well CPI-613 plus chemotherapy works in older patients with acute myeloid leukemia (AML) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is taking place across the United...

Read More

Evaluating quality of life after pembrolizumab treatment for classical Hodgkin lymphoma

Posted by on Jun 5, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 2 study evaluated the impact of pembrolizumab (Keytruda) on the quality of life of patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. This study concluded that the overall quality of life and health status was improved for these patients. Some background Most patients...

Read More

Evaluating the FMT regimen before a stem cell transplant in patients with aggressive non-Hodgkin lymphoma

Posted by on May 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of the FMT (fludarabine, melphalan, total body irradiation) regimen in patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that this regimen was well-tolerated and effective. Some background Many patients with aggressive NHL...

Read More

Looking for participants with advanced colorectal cancer to test a new targeted treatment with DS-8201a

Posted by on May 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness and safety of DS-8201a in the treatment of advanced HER2 positive colorectal cancer. The main outcome to be measured is the tumor response to the treatment and side effects.  The details The standard treatment to advanced colorectal cancers is surgery, chemotherapy and radiation...

Read More

Evaluating polatuzumab vedotin and pinatuzumab vedotin for relapsed or refractory NHL

Posted by on May 20, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) combined with either polatuzumab vedotin (pola) or pinatuzumab vedotin (pina) for patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that pola was associated with better...

Read More

Searching for patients with colorectal cancer to test this new treatment combination

Posted by on May 19, 2019 in Colorectal cancer | 0 comments

In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for advanced or unresponsive colorectal cancer (CRC) and other solid tumors.  The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...

Read More

Searching for patients with triple negative breast cancer to test this new treatment combination

Posted by on May 19, 2019 in Breast cancer | 0 comments

In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for triple negative breast cancer (TNBC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...

Read More